Literature DB >> 12515086

Polypoidal choroidal vasculopathy.

Antonio P Ciardella1, Irene M Donsoff, Lawrence A Yannuzzi.   

Abstract

Polypoidal choroidal vasculopathy seems to be a distinct clinical entity that should be differentiated from other types of CNV associated with AMD and other known choroidal degenerative, inflammatory, and ischemic disorders. The principle abnormality seen in PCV, notably the branching vascular network and polypoidal structures at the borders of the lesion, seem to be unique to the disorder. In patients with serosanguineous detachment of the pigment epithelium, particularly in those with increased risk factors such as African American or Asian race, ICG should be performed to evaluate the choroidal vascular abnormality to establish a more definitive diagnosis. If the characteristic vascular lesion of PCV is seen, a conservative approach to management should be taken unless there is a persistent or progressive exudative change that threatens the central macula. In that event, there may be a rationale for photo-coagulation treatment of leaking aneurysmal or polypoidal components within the vascular lesion, but not the entire vascular complex. Photodynamic therapy seems to be a promising therapeutic modality, but randomized clinical trials are needed to establish the efficacy and safety of the PDT treatment in the management of these patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12515086     DOI: 10.1016/s0896-1549(02)00053-6

Source DB:  PubMed          Journal:  Ophthalmol Clin North Am        ISSN: 0896-1549


  11 in total

1.  Angiographic features of transgenic mice with increased expression of human serine protease HTRA1 in retinal pigment epithelium.

Authors:  Sandeep Kumar; Zachary Berriochoa; Balamurali K Ambati; Yingbin Fu
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

2.  Detecting abnormalities in choroidal vasculature in a mouse model of age-related macular degeneration by time-course indocyanine green angiography.

Authors:  Sandeep Kumar; Zachary Berriochoa; Alex D Jones; Yingbin Fu
Journal:  J Vis Exp       Date:  2014-02-19       Impact factor: 1.355

3.  Hyperhomocysteinemia in patients with polypoidal choroidal vasculopathy: a case control study.

Authors:  Hui-Chen Cheng; Jorn-Hon Liu; Shui-Mei Lee; Po-Kang Lin
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

Review 4.  Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.

Authors:  Shiqi Yang; Jingke Zhao; Xiaodong Sun
Journal:  Drug Des Devel Ther       Date:  2016-06-02       Impact factor: 4.162

5.  Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy.

Authors:  Parveen Sen; S Vinay Kumar; Muna Bhende; Tarun Sharma
Journal:  Oman J Ophthalmol       Date:  2016 Sep-Dec

6.  Acute angle closure glaucoma secondary to polypoidal choroidal vasculopathy - a devastating complication.

Authors:  Prabu Baskaran; Manavi D Sindal; Pankaja Dhoble; Seema Ramakrishnan; Venkatesh Rengaraj; Pradeep Ramulu
Journal:  GMS Ophthalmol Cases       Date:  2017-01-05

7.  Idiopathic polypoidal choroidal vasculopathy in Thai patients with clinical and angiographic choroidal neovascularization.

Authors:  Chavakij Bhoomibunchoo; Yosanan Yospaiboon; Somanus Thoongsuwan; Duangnate Rojanaporn; Nawat Watanachai; Pichai Jirarattanasopa; Nattapon Wongcumchang; Atchara Amphornphruet; Sritatath Vongkulsiri; Eakkachai Arayangkoon
Journal:  Clin Ophthalmol       Date:  2017-02-09

8.  New developments in age-related macular degeneration.

Authors:  Lyndon da Cruz
Journal:  Community Eye Health       Date:  2008-09

Review 9.  Polypoidal choroidal vasculopathy: an update on therapeutic approaches.

Authors:  Raymond L M Wong; Timothy Y Y Lai
Journal:  J Ophthalmic Vis Res       Date:  2013-10

10.  EVEREST study report 3: diagnostic challenges of polypoidal choroidal vasculopathy. Lessons learnt from screening failures in the EVEREST study.

Authors:  Colin S Tan; Wei Kiong Ngo; Louis W Lim; Nikolle W Tan; Tock H Lim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-03       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.